Accutane (Isotretinoin) After Bariatric Surgery: What Prescribers and Patients Need to Know

What does the label say about dosing?

Absorica is dosed at 0.5 to 1 mg/kg/day and Absorica LD at 0.4 to 0.8 mg/kg/day, each in two divided doses for 15 to 20 weeks [1]. For adults with very severe disease, the respective limits may rise to 2 and 1.6 mg/kg/day [1]. Once-daily dosing is not recommended [1].

Absorica and Absorica LD are not substitutable on a mg per mg basis because bioavailability and recommended dosage differ [1]. Both come in a 20 mg strength, and those capsules are not interchangeable [1].

Does bariatric surgery change how isotretinoin is absorbed?

The labels do not address bariatric surgery. The clearest absorption numbers come from older-format isotretinoin labeling. After a single 80 mg dose in 74 healthy adults, AUC was 10,004 ngh/mL with a high-fat meal versus 3,703 ngh/mL fasting, and Cmax was 862 versus 301 ng/mL; half-life was about 21 hours either way [2]. That label says failure to take the drug with food will significantly decrease absorption, and it directs that the drug be taken with a meal [2]. It attributes the effect to isotretinoin's high lipophilicity [2].

Absorica is labeled for use without regard to meals, and Absorica LD has different bioavailability again [1].

What iPLEDGE and monitoring rules apply?

Every patient must be enrolled in iPLEDGE [1]. For patients who can get pregnant, the Absorica label requires a screening pregnancy test in a medical setting, a confirmatory test at least 30 days later after at least 30 days of contraception or committed abstinence, and a pregnancy test within 7 days before each prescription [1]. Patients who cannot get pregnant are still enrolled and must not share the drug or donate blood [1]. FDA approved iPLEDGE modifications on 2026-02-09, including, with prescriber permission, home pregnancy tests during and after treatment; FDA's page gives 2026-11-15 as the planned implementation date, and pre-treatment tests still must be done in a medical setting [3][4].

The Absorica label requires a fasting lipid profile and liver function tests in all patients before treatment, says to monitor lipid levels at regular intervals, and says to stop if hypertriglyceridemia cannot be controlled [1]. Marked triglyceride elevations were reported in about 25% of patients receiving Accutane in clinical trials [2]. The Absorica label also says to ask about psychiatric history before treatment and assess for depression, mood disturbance, psychosis or aggression at each visit, to avoid supplements containing vitamin A, and to avoid tetracyclines [1].